Vimian Group AB (publ) (VIMGF)
USD 3.5
(-14.29%)
USD 3.5
(-14.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 303.59 Million USD | 59.92% |
| 2022 | 189.84 Million USD | 33.71% |
| 2021 | 141.98 Million USD | 106.33% |
| 2020 | 68.81 Million USD | 1688.39% |
| 2019 | 3.84 Million USD | -35.23% |
| 2018 | 5.94 Million EUR | 118919.0% |
| 2017 | -5000.00 EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 150.01 Million USD | -48.63% |
| 2024 Q3 | 200.96 Million USD | 50.8% |
| 2024 Q1 | 274.02 Million EUR | -0.83% |
| 2023 Q1 | 207.97 Million USD | 9.55% |
| 2023 Q4 | 303.59 Million USD | 0.41% |
| 2023 Q3 | 302.36 Million USD | -3.55% |
| 2023 Q2 | 313.48 Million USD | 50.73% |
| 2023 FY | 303.59 Million USD | 59.92% |
| 2022 Q4 | 189.84 Million USD | -20.74% |
| 2022 FY | 189.84 Million USD | 33.71% |
| 2022 Q3 | 239.52 Million USD | -9.58% |
| 2022 Q2 | 264.89 Million EUR | 21.51% |
| 2022 Q1 | 218 Million EUR | 53.54% |
| 2021 Q4 | 141.98 Million EUR | 178.34% |
| 2021 FY | 141.98 Million USD | 106.33% |
| 2021 Q2 | 36.38 Million EUR | -38.39% |
| 2021 Q3 | 51.01 Million EUR | 40.19% |
| 2021 Q1 | 59.05 Million EUR | 5.01% |
| 2020 Q1 | 13.27 Million EUR | 0.0% |
| 2020 FY | 68.81 Million USD | 1688.39% |
| 2020 Q4 | 56.24 Million EUR | 0.0% |
| 2019 FY | 3.84 Million USD | -35.23% |
| 2018 FY | 5.94 Million EUR | 118919.0% |
| 2017 FY | -5000.00 EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | -13662.163% |
| Arrayit Corporation | 1.05 Million USD | -28660.805% |
| Atlantic International Corp. | 236.49 Thousand USD | -128271.435% |
| Biocept, Inc. | -788 Thousand USD | 38627.07% |
| Bioqual, Inc. | -12 Million USD | 2628.447% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -1335021.637% |
| DermTech, Inc. | 17.65 Million USD | -1619.783% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 153.03% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 4215.454% |
| iMD Companies, Inc. | 1.11 Million USD | -27105.798% |
| IDenta Corp. | 524.85 Thousand USD | -57743.603% |
| Interpace Biosciences, Inc. | 7.69 Million USD | -3845.845% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 1126522.191% |
| InVitro International | -313.14 Thousand USD | 97050.683% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -19287.611% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 42579806.732% |
| Medical Imaging Corp. | 3.79 Million USD | -7908.402% |
| NovelStem International Corp. | 3.52 Million USD | -8521.048% |
| Optigenex Inc. | 8.93 Million USD | -3298.187% |
| PharmChem, Inc. | -1.49 Million USD | 20415.221% |
| Proteome Sciences plc | 14.57 Million USD | -1983.215% |
| Response Genetics, Inc | -13.08 Million USD | 2419.986% |
| Rennova Health, Inc. | 14.82 Million USD | -1947.173% |
| RushNet, Inc. | 4.8 Million USD | -6223.747% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -223807.034% |
| Stella Diagnostics Inc. | 6.19 Million USD | -4802.154% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | -16913.757% |
| Todos Medical Ltd. | 38.31 Million USD | -692.382% |